VBI Vaccines Inc. is hoping that the price point for its new hepatitis B vaccine, Sci-B-Vac, as well as a favorable outcome against GlaxoSmithKline PLC’s Engerix-B, will give the trivalent vaccine a leg up in the market. Sci-B-Vac showed non-inferiority overall, and superiority in key subgroups, in its first Phase III trial.
The company hopes to make its new hepatitis B vaccine, a standard protocol for medical personnel and their patients, among others. “The number one determinant of adoption is cost,” VBI CEO Jeff Baxter told Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?